Tc-99m Tetrofosmin - GE Healthcare

Drug Profile

Tc-99m Tetrofosmin - GE Healthcare

Alternative Names: Myoview; MYOVIEW 30mL; MYOVIEW24; PPN-1011; Tc-99m tetrofosmin SPECT; Tc-99m-PPN1011; Technetium (99MTC) Tetrofosmin; Technetium-Tm99m-tetrofosmin

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amersham
  • Developer Amersham; GE Healthcare
  • Class Heavy metals; Radiosensitisers
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Coronary disorders; Ischaemia
  • Phase II Brain cancer

Most Recent Events

  • 07 Jun 2016 Chemical information added
  • 26 Apr 2016 Phase II clinical trials in Brain cancer (Diagnosis, In adults, In the elderly) in Germany (IV) (EudraCT2015-005573-21)
  • 23 Nov 2001 Registered for Coronary disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top